36
Participants
Start Date
August 31, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
November 30, 2014
fresolimumab
1 mg/kg total body weight administered intravenous (IV)
fresolimumab
4 mg/kg total body weight administered intravenous (IV)
Placebo
Placebo administered to match active treatment group
Investigational Site Number 4016, New York
Investigational Site Number 4003, New York
Investigational Site Number 4014, Rosedale
Investigational Site Number 4018, Philadelphia
Investigational Site Number 4304, Hamburg
Investigational Site Number 4002, Bethesda
Investigational Site Number 4004, Baltimore
Investigational Site Number 4404, Bergamo
Investigational Site Number 4403, Montichiari
Investigational Site Number 4504, Madrid
Investigational Site Number 4502, Madrid
Investigational Site Number 4005, Atlanta
Investigational Site Number 4008, Birmingham
Investigational Site Number 4001, Chattanooga
Investigational Site Number 4301, Düsseldorf
Investigational Site Number 4012, Ann Arbor
Investigational Site Number 4025, Detroit
Investigational Site Number 4302, Aachen
Investigational Site Number 4006, Rochester
Investigational Site Number 4024, St Louis
Investigational Site Number 4401, Bari
Investigational Site Number 4020, Dallas
Investigational Site Number 4027, Houston
Investigational Site Number 4029, Phoenix
Investigational Site Number 4405, Reggio Calabria
Investigational Site Number 4009, San Francisco
Investigational Site Number 4023, Stanford
Investigational Site Number 4013, Seattle
Investigational Site Number 4019, Springfield
Investigational Site Number 4022, Boston
Investigational Site Number 4104, Porto Alegre
Investigational Site Number 4503, Barcelona
Genzyme, a Sanofi Company
INDUSTRY